An Evaluation of the Optimal Dose of Tofacitinib Needed to Achieve LDA or Clinical Remission in Patients With Active Rheumatoid Arthritis (RA) as Measured From a Clinical and Structural Perspective When Treating to Target
Active, no longer recruiting
Phase of Trial: Phase III
Latest Information Update: 02 Feb 2017
At a glance
- Drugs Tofacitinib (Primary)
- Indications Rheumatoid arthritis
- Focus Therapeutic Use
- 23 Jan 2017 Planned End Date changed from 1 Jun 2016 to 1 Dec 2017.
- 23 Jan 2017 Planned primary completion date changed from 1 May 2016 to 1 Dec 2017.
- 23 Jan 2017 Status changed from recruiting to active, no longer recruiting.